Buscomint
Buscomint, licence 80113652: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Opella Canada Inc.
- NPN or DIN-HM
- 80113652
- Status
- Active licence
- Licence date
- 24 October 2021
- Revision date
- Not provided
- Form
- Capsule, remplie de liquide
- Route of administration
- Orale
- Application type
- Générale (non traditionelle)
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Mentha x piperita Source : Mentha x piperita - Sommité en fleurs (herbe) | 0.2 mL | Not calculated |
Non-medicinal ingredients
Citrate de triéthyle, Poly(sorbate) 80, Bleu brilliant FCF, Mono- et di- glycérides, Gélatine, Copolymère d'acide méthacrylique et d'acrylate d'éthyle, Eau purifiée, Lécithine, Glycérol, Oxyde de fer jaune, Triglycéride caprylique/caprique
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 18.0 ans | 1.0 Capsule | 3.0 Tous les jours |
| Enfants et Adolescents | minimum: 12.0 ans ; maximum: 18.0 ans | 1.0 Capsule | 3.0 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps relieve abdominal pain, abdominal cramping (spasms), gas (flatulence) distension (bloating), urgency of bowel movement and discomfort associated with Irritable Bowel Syndrome (IBS). Helps relieve abdominal pain and cramps (spasms) associated with Irritable Bowel Syndrom (IBS). Helps provide symptomatic relief of abdominal pain, minor spasms of the gastrointestinal tracts and flatulence (gas) associated with Irritable Bowel Syndrome (IBS). Helps relieve distension (bloating) associated with Irritable Bowel Syndrome (IBS). Helps relieve urgency of bowel movement associated with Irritable Bowel Syndrome (IBS).
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80113652
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.